Drug Resistance in Cancer Cells
(Sprache: Englisch)
The inability of cancer drugs to destroy metastatic tumors is the main reason cancer therapy fails. This comprehensive text offers current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance in cancer cells.
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
171.19 €
Produktdetails
Produktinformationen zu „Drug Resistance in Cancer Cells “
The inability of cancer drugs to destroy metastatic tumors is the main reason cancer therapy fails. This comprehensive text offers current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance in cancer cells.
Klappentext zu „Drug Resistance in Cancer Cells “
It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt - in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition - multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies - its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.
The inability of cancer drugs to destroy metastatic tumors is the major reason why cancer therapy fails. Even though the process of drug design has become exceedingly sophisticated in recent years, there is not a single drug available that is 100% effective against metastatic cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic/genetic differences in tumors, even those from tissue of origin. Although it is a generally accepted fact that the majority of cancers arise from a single precursor cell, it is naïve to consider that tumor is a collection of genetically identical cells. Genetic instability and accumulation of mutations are important hallmarks of cancer cells. This means that dividing cancer cells are able to acquire genetic and epigenetic changes that will favor their malignant phenotype. In view of this, it is fair to say that the cells in a given tumor may be similar but not identical. Therefore, when treated with a drug, the sensitive cells in a tumor succumb to the toxic effects of the drug, and resistant cells continue to survive and multiply. The tumor, which re-grows from these residual resistant cells, is not sensitive to the original drug.
Inhaltsverzeichnis zu „Drug Resistance in Cancer Cells “
Chapter 1:Drug resistance in cancer cells: a historical perspective (Macus T. Kuo, Houston, TX) or Victor Ling (Toronto, Canada)
Chapter 2:
Metastasis and drug resistance (Kapil Mehta, Houston, TX) or (Isiah Fidler, Houston, TX)
Chapter 3:
Apoptosis/autophagy and drug resistance (R.S. Krebel, Ontario, Canada) or (Yasuko Kondo, Houston, TX)
Chapter 4:
Cytokines and drug resistance (Livio Mallucci, London, UK)
Chapter 5:
Tissue transglutaminase and drug resistance (KapilMehta, Houston, TX)
Chapter 6:
Integrin signaling and drug resistance (David Cheresh, San Diego, CA)
Chapter 7:
Oxidative stress and drug resistance Boldogh, Istvan, UTMB, Galveston, TX)
Chapter 8:
NF-k B and drug resistance (Bharat B. Aggarwal, Houston, TX)
Chapter 9:
p53 and chemoresistance (Zahid Siddik, Houston, TX)
Chapter 10:
Resistance to differentiation therapy (Bulent Ozoplat, Houston, TX)
Chapter 11:
Assessment of cancer drug resistance by nuclear imaging (Sunil Krishnan, Houston, TX)
Chapter 12:
Overcoming drug resistance by phytochemicals (Bharat B. Aggarwal. Houston, TX) or (Marion M Chan, Philadelphia, USA)
Bibliographische Angaben
- 2009, 363 Seiten, Maße: 15,5 x 23,4 cm, Gebunden, Englisch
- Herausgegeben:Mehta, Kapil; Siddik, Zahid H.;Mitarbeit:Bates, Susan E.
- Herausgegeben: Kapil Mehta, Zahid H. Siddik
- Verlag: Springer, New York
- ISBN-10: 0387894446
- ISBN-13: 9780387894447
Sprache:
Englisch
Kommentar zu "Drug Resistance in Cancer Cells"
0 Gebrauchte Artikel zu „Drug Resistance in Cancer Cells“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Drug Resistance in Cancer Cells".
Kommentar verfassen